PSN Extra
FesariusTherapeutics closes oversubscribed $20M Series A, led by Jefferson Life Sciences and backed by NY Ventures and the American Society of Plastic Surgeons
June 10FesariusTherapeutics, a commercial-stage medical technology company reimagining dermal repair, today announced the close of an oversubscribed $20 million Series A financing round. The round was anchored by Jefferson Life Sciences (JLS) and joined by Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.), Empire State Development's NY Ventures and the American Society of Plastic Surgeons (ASPS), marking its inaugural institutional investment.
